Wall Street brokerages expect Natus Medical Incorporated (NASDAQ:BABY) to post $145.85 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Natus Medical’s earnings, with estimates ranging from $145.50 million to $146.20 million. Natus Medical posted sales of $107.70 million in the same quarter last year, which would indicate a positive year over year growth rate of 35.4%. The company is expected to report its next earnings report on Wednesday, February 7th.
According to Zacks, analysts expect that Natus Medical will report full year sales of $145.85 million for the current year, with estimates ranging from $515.10 million to $515.70 million. For the next financial year, analysts expect that the firm will report sales of $554.10 million per share, with estimates ranging from $552.40 million to $555.80 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Natus Medical.
Natus Medical (NASDAQ:BABY) last released its earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.02. Natus Medical had a negative net margin of 0.62% and a positive return on equity of 12.06%. The company had revenue of $122.60 million for the quarter, compared to analysts’ expectations of $122.41 million. During the same quarter in the previous year, the company earned $0.39 EPS. Natus Medical’s revenue for the quarter was up 34.9% on a year-over-year basis.
Several brokerages have commented on BABY. Zacks Investment Research upgraded shares of Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 price target on the stock in a research note on Tuesday, October 24th. BidaskClub cut shares of Natus Medical from a “sell” rating to a “strong sell” rating in a research note on Thursday, August 24th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. Natus Medical currently has an average rating of “Hold” and a consensus target price of $46.50.
In other Natus Medical news, VP Dong Chune Christopher Chung sold 12,642 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $42.91, for a total value of $542,468.22. Following the transaction, the vice president now directly owns 141,414 shares in the company, valued at approximately $6,068,074.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Robert A. Gunst sold 4,400 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $35.17, for a total transaction of $154,748.00. Following the completion of the transaction, the director now owns 50,850 shares in the company, valued at $1,788,394.50. The disclosure for this sale can be found here. Insiders have sold a total of 22,042 shares of company stock worth $902,266 over the last 90 days. Corporate insiders own 5.50% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Natus Medical by 2,085.6% during the third quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock valued at $102,000 after purchasing an additional 2,607 shares in the last quarter. Riverhead Capital Management LLC boosted its stake in shares of Natus Medical by 90.9% during the second quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock valued at $107,000 after purchasing an additional 1,364 shares in the last quarter. Sei Investments Co. boosted its stake in shares of Natus Medical by 29.7% during the second quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock valued at $119,000 after purchasing an additional 728 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Natus Medical during the third quarter valued at approximately $138,000. Finally, Victory Capital Management Inc. lifted its position in Natus Medical by 17.6% during the second quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock valued at $140,000 after acquiring an additional 560 shares during the last quarter. Institutional investors and hedge funds own 94.39% of the company’s stock.
Natus Medical (NASDAQ:BABY) traded down $0.55 on Friday, hitting $38.25. 232,012 shares of the company were exchanged, compared to its average volume of 384,591. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.36 and a current ratio of 4.21. Natus Medical has a 52 week low of $31.65 and a 52 week high of $43.60. The stock has a market cap of $1,207.22, a PE ratio of 25.00 and a beta of 0.84.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.